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Background: An appropriate level of sedation and pharmacological assist are essential during percutaneous 
transluminal balloon angioplasty (PTA). Ketamine provides good analgesia while preserving airway patency, 
ventilation, and cardiovascular stability with an opioid sparing effect suggesting that it would be ideal in combination 
with remifentanil and midazolam in spontaneously breathing patients. We evaluated the effect of a small dose of 
ketamine added to midazolam and remifentanil on analgesia/sedation for PTA procedures. 
Methods: Sixty-four patients receiving PTA were enrolled. The Control group received midazolam 1.0 mg i.v. and 
continuous infusion of remifentanil 0.05 μg/kg/min. The Ketamine group received, in addition, an intravenous bolus 
of 0.5 mg/kg ketamine. Patients’ haemodynamic data were monitored before remifentanil infusion, 5 min after 
remifentanil infusion, at 1, 3, 5, 30 min after incision, and at admission to the recovery room. Verbal numerical rating 
scales (VNRS) and sedation [OAA/S (Observer’s Assessment of Alertness/Sedation)] scores were also recorded. 
Results: The VNRS values at 1, 3, and 5 min after incision and OAA/S scores at 5 min after remifentanil infusion, 
and 1, 3, and 5 min after incision were lower in the Ketamine group than in the Control group. In the Control group, 
the VNRS value at 1 min after incision significantly increased and OAA/S values at 3, 5, and 30 min after incision 
significantly decreased compared to baseline values, while there were no significant changes in the ketamine group. 
Conclusions: A small dose of ketamine as an adjunct sedative to the combination of midazolam and remifentanil 
produced a better quality of sedation and analgesia than without ketamine and provided stable respiration without 
cardiopulmonary deterioration. (Korean J Anesthesiol 2011; 61: 308-314)
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Introduction
For successful percutaneous transluminal balloon angio-
plasty (PTA), sedation is essential so that patients remain 
immobile during the procedure in an uncomfortable environ-
ment. Since it takes a long time and is sensitive to motion 
artifacts [1], moderate sedation/analgesia and depressing 
consciousness that is, patients responding purposefully to 
verbal commands either alone or accompanied by light tactile 
stimulation with spontaneous ventilation, are usually required 
during PTA procedures [2].
Midazolam and various opioids are frequently used in com-
bi nation to provide sedation, anxiolysis and analgesia during 
short-term surgical procedures or interventional radiologic 
procedures [3]. Remifentanil has become popular lately as 
one of the intravenous opioids, because it can be infused 
continuously during simple procedures, regarding its excellent 
analgesic effect, and has a rapid onset and offset of action 
owing to a short context sensitive half-time [4,5]. Furthermore, 
as shown in a review reporting the incidence of serious 
cardiopulmonary complications and death as 5.4 and 0.3 per 
1,000, respectively in patients who underwent sedation with 
benzodiazepine and supplemental narcotics, the combination 
of both drugs could result in cardiopulmonary compromise 
[6]. To reduce the complications of intravenous anaesthetics, it 
is recommended that one considers combinations of various 
agents with different action mechanisms and at lower doses [7].
Ketamine in subhypnotic doses provides good analgesia 
while preserving airway patency, ventilation, and cardiovascular 
stability [8]. A small dose of ketamine may increase the 
analgesic potency of an opiate [9]. However, only a few studies 
have demonstrated the effect of ketamine on moderate sedation 
using a benzodiazepine and an opioid agent.
This study tested the hypothesis that adding a small dose 
of ketamine to midazolam and remifentanil combination can 
provide more effective analgesia/sedation for PTA procedures 
without adverse effects compared with a combination of 
midazolam and remifentanil only. 
Materials and Methods
From 2008 to 2010, we prospectively studied 64 patients aged 
27 to 84 years who underwent PTA. The study was approved by 
the hospital ethics committee, and written informed consent 
was obtained from all participants. All patients had American 
Society of Anesthesiologists (ASA) physical status I to III. 
Patients were excluded if they had ASA status IV, hepatic or 
renal insufficiency, history of allergy to the drugs used, need for 
inotropic agents, or need for mechanical ventilation. Patients 
were randomly assigned to one of the two treatment groups. 
During the entire study, an anesthesiologist who was blinded to 
patient group assignment recorded the variables.
No premedication was given to the patients. The Control 
group received normal saline, the same amount of 0.5 mg/kg of 
ketamine and then were managed with the standard protocol 
including intravenous injection of 1.0 mg of midazolam and 
continuous infusion of remifentanil 0.05 μg/kg/min. The 
Ketamine group received the sedation protocol consisting of an 
intravenous bolus of 0.5 mg/kg ketamine followed by a bolus 
of 1.0 mg midazolam and continuous infusion of remifentanil 
0.05 μg/kg/min. If signs of insufficient analgesia (facial grimace, 
movement, sudden increase in heart rate, spontaneous 
complaint of pain) were observed, an additional intravenous 
bolus of remifentanil 0.2 μg/kg was injected without changing 
the infusion rate of remifentanil in both groups. A local 
anesthetic agent was injected into the incision site before 
the incision by a cardiologist. Oxygen was delivered by a face 
mask to all patients throughout the procedure. Any episodes of 
hypoventilation (spontaneous RR < 8 /min), desaturation (SpO2 
< 90%) or apnea during the infusion phase was recorded and 
the jaw thrust maneuver was applied to patients, if necessary. 
When those episodes persisted even with stimulation, the 
remifentanil infusion rate was reduced to 0.03 μg/kg/min. 
The patients were monitored for mean arterial blood 
pressure (MAP), heart rate (HR), peripheral oxygen saturation 
(SpO2), and respiratory rate (RR) before the remifentanil 
infusion, 5 min after remifentanil infusion (baseline value), at 
1, 3, 5, 30 min after incision, and at admission to the recovery 
room. The verbal numerical rating scales (VNRS), sedation 
score [OAA/S (Observer’s Assessment of Alertness/Sedation)] 
and the presence of nausea, vomiting, itching sense or apnea 
were recorded at the same time points. The quality of analgesia 
was assessed by VNRS using and 11 point scale (0-10) [9]. The 
patient was asked to rate the intensity of the pain experienced 
on the scale of with 0 being “no pain” and 10 “the worst pain 
imaginable”. Such scales have the advantages of being quick 
and simple, require no equipment, and they are easy to 
understand [10]. The OAA/S scale was developed to measure 
the level of alertness in subjects who are sedated and is defined 
in Appendix A. The duration of remifentanil infusion, total 
amount infused, and the frequency of bolus injection were 
recorded and the degree of satisfaction (1-4) of the surgeon and 
the patients were evaluated. Time to Aldrete score > 9 was also 
recorded at the recovery room. The Aldrete score is a measure 
of recovery after anesthesia that includes level of consciousness, 
physical activity, hemodynamic stability, respiratory stability, 
and oxygen saturation status; scores for each category were 0 to 2.
Statistical analysis was performed using SPSS 13.0 (SPSS Inc., 
Chicago, IL, USA). The normality of distribution was assessed 
with a q-q plot and the Shapiro-Wilk test. Patient characteristics 
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(age, height, weight, duration of remifentanil infusion) were 
analysed using an independent t-test. Categorical variables 
(remifentanil bolus number, apnea after bolus, amnesia at 
recovery room and side effects) were evaluated by a χ2 test or 
a Fisher’s exact test when appropriate. Repeated measures 
analysis of variance (ANOVA) was used for the comparison 
of and VNRS scores for pain. If significant differences were 
detected, differences between two means were compared by 
an independent t-test with Bonferroni correction. Comparisons 
between the two groups with regard to pain and sedation scores 
were done with the Mann-Whitney U test, and intragroup 
comparisons were done with the Wilcoxon signed rank test. All 
values were expressed as mean ± standard deviation, median 
(interquartile range) or the number of patients. A P value < 0.05 
was considered statistically significant. Sample size calculations 
were based on previous studies. To detect a two-point difference 
in VNRS score for pain (two-sided α of 5% and β of 20%), 32 
subjects were required in each group.
Results
Demographic and clinical parameters were comparable 
between the groups. The duration of remifentanil infusion (80 ± 
39 min vs. 71 ± 28 min) and the total amount infused (278 ± 164 
μg vs. 246 ± 176 μg), apnea after bolus (4 cases vs. 3 cases) were 
higher in the Control group but none of these differences were 
statistically significant (Table 1). 
The satisfaction scale (1 to 4) of the surgeons and the patients 
were high in both groups (4 vs. 4). Between group differences 
in haemodynamic and respiratory parameters during and after 
the procedures were not significant except for respiratory rates. 
After skin incision, respiratory rates were significantly lower in 
Table 1. Patient Demographics and Preoperative Clinical Data
Control group
(n = 32)
Ketamine group
(n = 32)
P value
Age (years)
Female gender, # (%)
ASA I
ASA II
ASA III
Height (cm)
Weight (kg)
Duration of procedure (min)
Remifentanil infusion duration (min)
Total amount of remifentanil infused (µg)
Number of remifentanil bolus injections
Apnea after remifentanil bolus injection
Amnesia at the recovery room
Patient satisfaction (1-4)
Surgeon satisfaction (1-4)
Time to Aldrete score >9 (min)*
67 ± 11
11 (34.4)
3 (9.4)
29 (90.6)
0
163.2 ± 7.9
63.4 ± 12.1
82 ± 29
80 ±39
278 ±164
1.3 ± 1.3
4 (12.5)
12 (37.5)
4 (3-4)
4 (3-4)
5.1 ± 5.3
61 ± 11
8 (25.0)
3 (9.4)
28 (87.5)
1 (3.1)
163.2 ± 8.2
63.4 ± 8.8
76 ± 30
70 ± 28
264 ± 157
1.0 ± 1.5
3 (9.4)
16 (50.0)
4 (3-4)
3.5 (3-4)
3.8 ± 4.3
0.055
0.412
0.601
0.983
0.945
0.488
0.211
0.729
0.479
0.689
0.313
0.843
0.319
0.287
Data are expressed as mean ± SD or number of patients (%). ASA: American Society of Anesthesiologists. *Measured after recovery room 
admission.
Table 2.  Haemodynamic Data 
Group T0 T1 T2 T3 T4 T5 T6
RR
MAP
HR
SpO2
Control
Ketamine
Control
Ketamine
Control
Ketamine
Control
Ketamine
20 ± 2†
21 ± 2†
100 ± 21
98 ± 17
73 ± 17
70 ± 12
99 ± 2
98 ± 1
18 ± 3
16 ± 3
96 ± 17
99 ± 15
70 ± 17
71 ± 12
99 ± 1
99 ± 1
20 ± 4†
16 ± 3*
100 ± 20
95 ± 14
70 ± 17
69 ± 13
99 ± 2
99 ± 2
23 ± 4† 
16 ± 5* 
94 ± 17
94 ± 15
72 ± 16
68 ± 13
99 ± 2
99 ± 2
20 ± 4† 
15 ± 4* 
90 ± 16
91 ± 16
70 ± 16
69 ± 12
99 ± 2
97 ± 10
21 ± 6† 
15 ± 4*
89 ± 15
96 ± 15
71 ± 16
69 ± 12
99 ± 2
99 ± 2
19 ± 3
16 ± 3* 
90 ± 15
97 ± 14
73 ± 16
70 ± 11
99 ± 1
99 ± 2
Data are expressed as mean ± SD. T0: before remifentanil infusion, T1: 5 min after remifentanil infusion, T2: 1 min after incision, T3: 3 min after 
incision, T4: 5 min after incision, T5: 30 min after incision, T6: admission to recovery room, RR: respiratory rate, MAP: mean arterial pressure, 
HR: heart rate, SpO2: peripheral oxygen saturation. *P < 0.05 compared with group 1 at each time point of measurement. 
†P < 0.01 compared 
with T1.
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the Ketamine group compared to the Control group (Table 2). 
Also, in the Control group, the respiratory rates significantly 
increased at 1, 3, 5, and 30 min after incision compared with 
the point when remifentanil was initially infused. In both 
groups, the respiratory rates significantly decreased 5 min after 
remifentanil infusion compare to rates before infusion.
VNRS values at 1, 3, and 5 min after incision were signifi-
cantly lower in the Ketamine group than in the Control group. 
In the Ketamine group, lower OAA/S scores were found at 5 min 
after remifentanil infusion, and 1, 3, and 5 min after incision 
than in the Control group. In the Control group, VNRS value at 
1 min after incision significantly increased and OAA/S values at 
3, 5, and 30 min after incision significantly decreased compared 
to baseline values, while there were no significant changes in 
VNRS and OAA/S values in the Ketamine group (Table 3). 
Apnea without a bolus developed in one patient in the 
Control group and two patients in the Ketamine group and 
all patients recovered self respiration after tactile stimulation 
without significant desaturation. Remaining side effects during 
the study were comparable between the groups and were not 
significant in both groups (Table 4). 
Discussion
In this prospective study evaluating the effects of a small 
dose of ketamine as an adjunct sedative to the combination of 
midazolam and remifentanil in patients undergoing PTA, we 
found that the addition of a low dose of ketamine produced a 
better quality of sedation and analgesia than without ketamine, 
although the patients’ satisfaction scores were high enough 
even in the Control group. The addition of ketamine provided 
more stable respiration without cardiopulmonary deterioration. 
Sedation with various degrees of depth and duration is 
essential for both the patients’ and interventionists’ conveni-
ences for interventional procedures. Medications should be 
administered to achieve: 1. adequate analgesia, sedation, 
anxiolysis, and amnesia during the procedures, 2. control of 
unwanted motor behavior that inhibits the performance of 
procedures, 3. rapid return of the patient to consciousness, and 
4. less risk of adverse events. For stable conditions of sedation 
and haemodynamics, continuous intravenous infusion rather 
than repetitive bolus doses [10] and combination of various 
agents having different action mechanisms are recommended. 
Therefore, combined use of analgesics and hypnotics, with 
some of them being short acting agents that permit continuous 
infusion, has been considered as a reasonable and safe sedation 
regimen for interventional procedures. 
Midazolam, a short acting benzodiazepine, has been the 
most commonly used sedative agent for PTA. Midazolam 
produces dose-related sedation, amnesia, and anxiolysis, but 
has a poor analgesic effect, and recovery may be prolonged 
due to its cumulative hypnotic effect. Therefore, midazolam 
usually requires the use of an adjunctive analgesic agent. The 
synergistic effect of opioids and midazolam in combination 
is well known [11-14] and currently an alternative sedation 
protocol based on remifentanil with midazolam is widely 
used. Remifentanil is an ultra-short acting opioid popular in 
anaesthetic practices that is a mu-receptor agonist. The unique 
pharmacology of remifentanil, its rapid offset in particular, has 
attracted clinicians and investigators recently for procedures 
requiring a brief and intense opioid effect. The rapid offset 
of remifentanil, demonstrated by its extremely short context 
sensitive half-time (3-5 min), and which occurs regardless of 
the duration of the infusion, also allows continuous infusion 
for long procedures [15]. However, as for other opioids, 
remifentanil increases the risk of repetitive apnea and may 
produce dose dependent respiratory depression with delayed 
awakening. The most common side effects of combined use of 
midazolam and remifentanil are respiratory depression and 
patients’ intolerance as a result of prolonged procedures [3]. 
Table 3.  Pain and Sedation Score
Group T1 T2 T3 T4 T5 T6
VNRS
OAA/S
Control
Ketamine
Control
Ketamine
0 (0, 1.75)
0 (0, 0)
4 (4, 4)
3 (0.25, 4)*
2 (1.25, 5)†
0 (0, 1)* 
4 (3, 4)
3 (1, 4)*
1.5 (0, 2.75)
0 (0, 1)* 
3 (3, 4)† 
2.5 (1, 4)*
1.5 (0, 3)
0 (0, 0)* 
3 (3, 4)†
2 (1, 4)* 
0 (0, 1)
0 (0, 2)
3 (3, 4)†
3 (1.25, 4)
0 (0, 1)
0 (0, 1.75)
4 (3.25, 4)
4 (1.25, 4)
Data are expressed as median (interquartile range). T1: 5 min after remifentanil infusion, T2: 1 min after incision, T3: 3 min after incision, 
T4: 5 min after incision, T5: 30 min after incision, T6: admission to recovery room, VNRS: verbal numerical rating scales, OAA/S: Observer’s 
Assessment of Alertness/Sedation Scale. *P < 0.05 compared with group 1 at each time point. †P < 0.01 compared with T1. 
Table 4.  Adverse Effects in the Two Groups
Control group
(n = 32)
Ketamine group
(n = 32)
Apnea
Nausea
Vomiting
Itching
1
1
0
2
2
0
0
0
Data are expressed as number of patients.
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Ketamine is a nonspecific N-methyl-d-aspartate (NMDA) 
receptor antagonist that provides intrinsic analgesia and 
apparent anesthesia with relative hemodynamic stability and 
protects airway reflexes [16,17]. Furthermore, a small-dose of 
ketamine increases thalamic sensory output and arousal [18]. 
Therefore, the administration of intravenous ketamine appears 
to be a safe and useful technique for monitored anesthesia care 
in the ambulatory setting. Ketamine has an additive hypnotic 
effect when used with midazolam [19]. In addition, a small dose 
of ketamine was reported to reduce postoperative hyperalgesia 
and opioid induced intolerance, especially tolerance to 
remifentanil. Both additive and beneficial effects of ketamine on 
midazolam and/or remifentanil effects would exert a beneficial 
effect on cardiopulmonary stability by decreasing the needed 
dose of both drugs. Studies on the combined use of ketamine and 
remifentanil are now being actively performed, but are mostly 
limited to patients undergoing general anesthesia [20,21]. 
In this study, we added a small dose of ketamine to a combi-
nation of midazolam and remifentanil for more satisfactory 
sedation with limited effects on cardio-respiratory function 
in patients undergoing PTA. We observed that the VNRS and 
OAA/S scores were significantly lower in the Ketamine group, 
demonstrating a better quality of sedation. Among various 
interventional procedures, PTA requires a long duration and 
motionless field. Therefore, deep sedation with spontaneous 
ventilation is needed during PTA. Frequently, a large amount of 
repetitive midazolam or a higher dose of remifentanil infusion 
are required, which may result in delayed awakening or 
significant respiratory depression, especially in compromised 
patients. Therefore, this study demonstrated that a small 
dose of ketamine given as a pre-procedural bolus intensified 
the analgesic and sedative effects of the drug combination 
without cardiorespiratory depression could have a significant 
clinical impact on PTA procedures. Most patients in the 
Ketamine group were in a painless and motionless state during 
the procedures, and their haemodynamics and respiration 
remained stable without adverse events. Interestingly, although 
ketamine was known to counteract opioid induced respiratory 
depression [22], the respiratory rates were significantly lower 
in the Ketamine group compared to the Control group. In 
both groups, the respiratory rates significantly decreased 
after remifentanil infusion (before the skin incision). Only 
in the Control group was the respiratory rate increased after 
incision, and it was higher than that in a previous study using 
midazolam and remifentanil [23]. This proves the superior 
sedative effect of the Ketamine group with regards to sedative 
quality. Although statistically not significant, heart rates were 
slightly lower throughout the procedure in the Ketamine group, 
which is opposite to its known characteristic of increasing heart 
rate. This may also have resulted from the effective sedation of 
ketamine pretreatment. There were no patients whose arterial 
oxygen saturation decreased below 90% in either group. Three 
patients developed apnea. All patients recovered self respiration 
immediately after verbal or gentle tactile stimulation without 
significant desaturation. The dose of remifentanil used in this 
study was significantly lower than in other studies of conscious 
analgesia and sedation [23,24] and, therefore, opioid induced 
respiratory depression did not occur in our study. This was 
also associated with the fact that the expected opioid sparing 
effect of ketamine was not observed in this study. Based on 
the low VNRS and OAA/S scores as well as high satisfaction 
scores of both patients and care providers for both groups, we 
believe adequate sedation and analgesia were provided during 
the procedures, even in the Control group. The difference in 
remifentanil dosage from other studies might be related to 
racial differences. Significantly lower OAA/S value at 5 min 
after remifentanil infusion shows that ketamine may rapidly 
intensify the depth of sedation. Accordingly, in the Ketamine 
group, the VNRS score did not increase even after the skin 
incision, unlike the Control group. The sedation score at 30 min 
after skin incision, and time to an Aldrete score >9 points in 
the recovery room were similar between the two study groups, 
which demonstrates that the addition of ketamine did not delay 
awakening of the patients after the procedures. 
Large doses of ketamine (>2 mg/kg) are frequently associated 
with unpleasant side effects including hallucinations, dreams, 
cognitive decline, and emergence confusion. Also, ketamine 
can cause involuntary muscle movement, potentially limiting 
its suitability in interventional radiology procedures. However, 
a small bolus of ketamine (0.5-1.0 mg/kg) without continuous 
infusion rarely causes such side effects [25], and there were 
no patients complaining of hallucinations or confusion in this 
study. This result is consistent with other studies, where a single 
bolus of ketamine was used. 
In some studies, remifentanil elicited hyperalgesia (increased 
sensitivity to noxious stimuli) and rapid intolerance, which 
was associated with the intraoperative opioid dosage. Despite 
the fact that ketamine was reported to mitigate remifentanil 
induced hyperalgesia during the postoperative period, we could 
not assess the presence of hyperalgesia after the procedure. 
This might be a limitation of this study, although we believe 
that the degree of pain after PTA is usually mild and the dose 
of ketamine in this study was not enough to exert a preventive 
effect on remifentanil induced hyperalgesia. 
In conclusion, a small dose of ketamine as an adjunct 
sedative to the combination of midazolam and remifentanil in 
patients undergoing PTA produced a better quality of sedation 
and analgesia than without ketamine, and provided stable 
respiration without cardiopulmonary deterioration.
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<Appendix A>  OAA/S Scale
Response Speech Facial expression Eyes
Composite 
score
Responds readily to name spoken in 
  normal tone
Lethargic response to name spoken in 
  normal tone
Responds only after name is called 
  loudly or repeatedly
Responds only after mild prodding or 
  shaking
Does not respond to mild prodding or 
  shaking
Does not respond to noxious stimulus
Normal
Mild slowing or   
  thickening
Slurring or prominent   
  slowing
Few recognizable words
Normal
Mild relaxation
Marked relaxation  
  (slack jaw)
Clear, no ptosis
Glazed or mild ptosis
  (less than half the eye)
Glazed and marked ptosis   
  (half the eye or more)
5
4
3
2
1
0
OAA/S: Observer’s Assessment of Alertness/Sedation.
